BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
June 17, 2009
View Archived Issues
Pharnext, Ipsen in $126M Deal for Neuromuscular Compound
Drug repositioning specialist Pharnext out-licensed its lead program in the chronic neuromuscular disease, Charcot-Marie-Tooth, to Ipsen SA in a deal with a value of at least €91 million ($US126.1 million). (BioWorld International)
Read More
£22.4M and a New CEO 'Transforming' for Allergy
Read More
Meningitis Study Could Speed Drugs to Pass Blood-Brain Barrier
Read More
ASCO Data Spark Biotech to Focus on Private Equity
Read More
Xenon Snags Yet Another Cardiovascular Drug Deal
Read More
Phase II Lupus Data Boost HGSI, but Analysts Wary on Phase III
Read More
Other News To Note
Read More